SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-10-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of SKB264 monotherapy in
subjects with selected advanced solid tumors.The study is divided into two parts: the Part Ⅰ
consists of 4 cohorts, and the Part Ⅱ for expansion. Eligible subjects will receive SKB264
monotherapy, until there is no longer clinical benefit, intolerable toxicity, discontinuation
of study treatment required by the subject, or other protocol-specified treatment
discontinuation criteria, whichever occurs first.
Phase:
Phase 2
Details
Lead Sponsor:
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.